Target Name: MID2
NCBI ID: G11043
Review Report on MID2 Target / Biomarker Content of Review Report on MID2 Target / Biomarker
MID2
Other Name(s): RNF60 | TRIM1_HUMAN | midin 2 | tripartite motif protein 1 | Tripartite motif protein 1 | Probable E3 ubiquitin-protein ligase MID2 (isoform 1) | Probable E3 ubiquitin-protein ligase MID2 | Midline-2 | MID2 variant 1 | FLJ41813 | midline 2 | XLID101 | Tripartite motif-containing protein 1 | RING finger protein 60 | midline defect 2 | RING-type E3 ubiquitin transferase MID2 | Midin-2 | FLJ37715 | Midline 2, transcript variant 1 | TRIM1 | OTTHUMP00000023817 | tripartite motif-containing protein 1 | MRX101 | OTTHUMP00000023816 | Midin 2 | FXY2 | Midline defect 2

MID2: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

MID2 (middle-length interspacer domain) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. MID2 is a key regulator of gene expression and has has been shown to play a role in the regulation of stem cell proliferation and differentiation, as well as in the development and progression of various diseases.

MID2 has been shown to be involved in a variety of cellular processes, including cell growth, cell cycle progression, and the regulation of gene expression. MID2 has been shown to interact with a variety of protein molecules, including the transcription factors CDK4 and CDK6, as well as with the RNA binding protein RISC (RNA-stimulated RNA binding protein).

One of the most promising aspects of MID2 is its potential as a drug target. MID2 has been shown to be highly expressible in various tissues and has been shown to play a role in the development and progression of various diseases, including cancer. MID2 has also has been shown to be a good candidate for small molecule inhibitors, such as drugs that can inhibit the activity of MID2 and its downstream targets.

In addition to its potential as a drug target, MID2 has also been shown to be a potential biomarker for a variety of diseases. MID2 has been shown to be highly upregulated in various diseases, including cancer, and has been shown to be a good candidate for use as a diagnostic or predictive marker for these diseases.

MID2 is also of interest as a potential therapeutic target in neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These diseases are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to contribute to the degenerative changes that occur in these diseases. MID2 has been shown to play a role in the regulation of neurofibrillary tangles and has been shown to be involved in the development and progression of these diseases.

In conclusion, MID2 is a non-coding RNA molecule that has been shown to be involved in a variety of cellular processes and has been identified as a potential drug target and biomarker in various diseases. Further research is needed to fully understand the role of MID2 in these diseases and to develop effective treatments.

Protein Name: Midline 2

Functions: E3 ubiquitin ligase that plays a role in microtubule stabilization. Mediates the 'Lys-48'-linked polyubiquitination of LRRK2 to drive its localization to microtubules and its proteasomal degradation in neurons. This ubiquitination inhibits LRRK2 kinase activation by RAB29 (PubMed:35266954)

The "MID2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MID2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIDEAS | MIDEAS-AS1 | MIDN | MIEF1 | MIEF2 | MIEN1 | MIER1 | MIER2 | MIER3 | MIF | MIF-AS1 | MIF4GD | MIGA1 | MIGA2 | MIIP | MILIP | MILR1 | MIMT1 | MINAR1 | MINAR2 | MINCR | MINDY1 | MINDY2 | MINDY2-DT | MINDY3 | MINDY4 | Minichromosome maintenance (MCM) 2-7 helicase complex | MINK1 | MINPP1 | MIOS | MIOX | MIP | MIPEP | MIPEPP3 | MIPOL1 | MIR1-1 | MIR1-1HG | MIR1-2 | MIR100 | MIR100HG | MIR101-1 | MIR101-2 | MIR10394 | MIR10396B | MIR10399 | MIR103A1 | MIR103A2 | MIR103B1 | MIR103B2 | MIR105-1 | MIR105-2 | MIR10527 | MIR106A | MIR106B | MIR107 | MIR10A | MIR10B | MIR11181 | MIR11400 | MIR11401 | MIR1178 | MIR1179 | MIR1180 | MIR1181 | MIR1182 | MIR1183 | MIR1184-1 | MIR1184-2 | MIR1184-3 | MIR1185-1 | MIR1185-2 | MIR1193 | MIR1197 | MIR1199 | MIR1200 | MIR1202 | MIR1203 | MIR1204 | MIR1205 | MIR1206 | MIR1207 | MIR1208 | MIR12129 | MIR12135 | MIR12136 | MIR122 | MIR1224 | MIR1225 | MIR1226 | MIR1227 | MIR1228 | MIR1229 | MIR1231 | MIR1233-1 | MIR1233-2 | MIR1234 | MIR1236 | MIR1237 | MIR1238 | MIR124-1